Skip to main content

Enhancing Patient Safety: Addressing the Potentially Fatal Consequences of Undetected Hemolysis at the Point of Care

Tracking # 20-1342720

Price not reported

5 (1 ratings)
Learn more
CE Broker Reporting Reported automatically
Method Broadcasted Interactive Event
Dates Contact provider

Course overview

Join us for an insightful webinar exploring patient safety risks and potentially fatal outcomes, due to undetected hemolysis at the point of care (POC). This webinar will cover patient cases where undetected hemolysis caused adverse patient outcomes, and will highlight how undetected hemolysis is exacerbated by insufficient awareness of blood gas testing limitations related to hemolysis. The importance of adopting solutions with integrated hemolysis detection to prevent these potential high-risk situations will be emphasized. Through expert-led discussions and actionable frameworks, attendees will learn how to adopt and scale technologies that drive efficiency across diverse hospital environments. Whether you're navigating resource constraints or planning future growth, this session offers practical guidance to strengthen your lab's impact and resilience.

Subject areas

This course counts toward the state boards and subject areas below.

American Board of Clinical Chemistry

Clinical Chemistry Diplomate

1h Category 1

Molecular Diagnostics Diplomate

1h Category 1

Toxicological Chemistry Diplomate

1h Category 1

Florida Board of Clinical Laboratory Personnel

Clinical Laboratory Director

1h General

Clinical Laboratory Supervisor

1h General

Clinical Laboratory Technician

1h General

Clinical Laboratory Technologist

1h General

Public Health Director

1h General

Public Health Supervisor

1h General

Public Health Technologist

1h General

Disclosure statements

The Association for Diagnostics & Laboratory Medicine (formerly AACC) is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.


The following faculty reported financial relationships:

  • Nam Tran, PhD, HCLD (ABB), FADLM
  • Honorarium: Nova Biomedical, Thermo, Diasorin
  • Consulting Fees: Roche, Radiometer
  • Committee and/or Advisory Board: ADLM Board of Directors
  • Alan Wu, PhD, DABCC
  • Honorarium: Werfen
  • Consulting Fees: Werfen
  • Committee and/or Advisory Board: Werfen Advisory Board


The following faculty reported no financial relationships:

  • Robert Cooper, MD, MBA, MPH


Learner Feedback